Investments by Leading Players In Differentiated Offering Is Expected to be Highly Supplemental to Intramuscular Live-attenuated Vaccines Growth Finds Fact.MR
Investments by Leading Players In Differentiated Offering Is Expected to be Highly Supplemental to Intramuscular Live-attenuated Vaccines Growth Finds Fact.MR
Published by top news
Posted on August 13, 2021
Incessantly rising demand in response to the unbridled spread of COVID-19 has pushed the respiratory virus vaccines market to the fore. Fact MR’s recent study on the market is intended to offer insights into the future and discover hidden opportunities for market players. Increasing R&D investments and initiatives are aiding exponential growth in the market.
Considering that the aforementioned trend will show no signs of slowing down, Fact.MR projects the demand for respiratory virus vaccines to rise at an 8% CAGR from 2020 and 2030. With some prominent international organizations increasing their funding towards research & development, the market is expected to gain significant impetus over the coming years. For instance, the National Institute of Allergy and Infectious Diseases (NIAID) has recently announced a funding of US$ 51 Mn towards the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, with the intention of developing influenza vaccines.
The threat posed by avian influenza to the global population is possibly at an all-time high in recent times. The tightening noose of COVID-19, coupled with the identification of numerous novel respiratory viruses, is underpinning the need for the development of therapeutic and preventive models. Inventing vaccines is potentially the most crucial step taken towards the prevention of widespread viral infections and the reduction of mortality associated with them. Against the backdrop of the ongoing pandemic, demand for respiratory virus vaccines is expected to surge exponentially. Fact MR expects the respiratory virus vaccines market size to surpass US$ 14 Bn valuation by the end of 2030.
“Demand witnessed in the respiratory virus vaccines market is forecast to surge especially on account of the unprecedented outbreak of COVID-19. An increasing number of market players are expected to focus on research initiatives, to gain a competitive advantage in this space,” says a Fact.MR analyst.
Key Takeaways from Respiratory Virus Vaccines Market Study
The global respiratory virus vaccines market is expected to surpass a valuation of US$ 14 Bn by 2030.
North America currently dominates the global market for respiratory virus vaccines.
Based on type, inactivated/ killed vaccines’ hegemony will continue through 2030.
Based on indication, demand from the influenza segment will remain comparatively higher.
Among all the age groups, demand from the pediatric segment is likely to be higher.
Physician offices are currently dominating among the end users.
Fact.MR has studied the respiratory virus vaccines market with detailed segmentation on the basis of type, route of administration, indication, age group, end user, and key regions.
Type
Route of Administration
Indication
Age Group
End User
Region
Inactivated/Killed Vaccines
Live-attenuated Vaccines
Recombinant Vaccines
Intramuscular
Intranasal
Subcutaneous
Influenza
Measles, Mumps & Rubella
Coronavirus Disease (COVID-19)
Others
Pediatric
Adults
Physician Offices
Hospitals
Clinics
Pharmacies/Stores
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Respiratory Virus Vaccines Market Insights by Route of Administration
Based on route of administration, the market can be segmented into intramuscular, subcutaneous, and intranasal. Of these, the intramuscular segment is likely to remain dominant throughout the period of forecast.
Respiratory Virus Vaccines Market Insights by Indication
Based on indication, the global market can be classified into mumps & rubella, measles, influenza, coronavirus disease (COVID-19), and others. Of these, the influenza segment currently holds prominence. Rising cases of influenza around the world have made effective vaccination programs highly necessary for children. Over the coming years, the market will witness rising demand from the COVID-19 segment. In the absence of proper vaccination, governments around the world are leaving no stone unturned to discover a potential cure.
The Respiratory Virus Vaccines market report answers important questions which include:
What does the status of the Respiratory Virus Vaccines market look like after the forecast period?
Which region has the highest contribution to the global Respiratory Virus Vaccines market and why?
Which players remain at the top of the global Respiratory Virus Vaccines market?
What opportunities are available for the Respiratory Virus Vaccines market players to expand their production footprint?
Which segment has the maximum impact on the global Respiratory Virus Vaccines market?
Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape
Rising Burden of Respiratory Illnesses Fuelling Demand
According to the World Health Organization, nearly 290,000 to 650,000 people die every year around the world due to flu-related illnesses. Rising incidence of respiratory illnesses and subsequently increasing demand for vaccines to prevent respiratory infections are the chief drivers of the global market.
With leading pharmaceutical companies racing to be the first to develop and launch a vaccine for the novel coronavirus, the respiratory virus vaccines market is expected to surge exponentially through the course of the forecast period.
Why Opt For Fact.MR?
Various analysis methods to deliver precise market information.
Digital technologies to facilitate clients with updated market solutions.
Multi-disciplinary approach to provide accurate insights of different industries.
Data collection from extensive primary and secondary research.
Round-the-clock availability to serve clients across the world.
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
Incessantly rising demand in response to the unbridled spread of COVID-19 has pushed the respiratory virus vaccines market to the fore. Fact MR’s recent study on the market is intended to offer insights into the future and discover hidden opportunities for market players. Increasing R&D investments and initiatives are aiding exponential growth in the market.
Considering that the aforementioned trend will show no signs of slowing down, Fact.MR projects the demand for respiratory virus vaccines to rise at an 8% CAGR from 2020 and 2030. With some prominent international organizations increasing their funding towards research & development, the market is expected to gain significant impetus over the coming years. For instance, the National Institute of Allergy and Infectious Diseases (NIAID) has recently announced a funding of US$ 51 Mn towards the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, with the intention of developing influenza vaccines.
The threat posed by avian influenza to the global population is possibly at an all-time high in recent times. The tightening noose of COVID-19, coupled with the identification of numerous novel respiratory viruses, is underpinning the need for the development of therapeutic and preventive models. Inventing vaccines is potentially the most crucial step taken towards the prevention of widespread viral infections and the reduction of mortality associated with them. Against the backdrop of the ongoing pandemic, demand for respiratory virus vaccines is expected to surge exponentially. Fact MR expects the respiratory virus vaccines market size to surpass US$ 14 Bn valuation by the end of 2030.
“Demand witnessed in the respiratory virus vaccines market is forecast to surge especially on account of the unprecedented outbreak of COVID-19. An increasing number of market players are expected to focus on research initiatives, to gain a competitive advantage in this space,” says a Fact.MR analyst.
Key Takeaways from Respiratory Virus Vaccines Market Study
The global respiratory virus vaccines market is expected to surpass a valuation of US$ 14 Bn by 2030.
North America currently dominates the global market for respiratory virus vaccines.
Based on type, inactivated/ killed vaccines’ hegemony will continue through 2030.
Based on indication, demand from the influenza segment will remain comparatively higher.
Among all the age groups, demand from the pediatric segment is likely to be higher.
Physician offices are currently dominating among the end users.
Fact.MR has studied the respiratory virus vaccines market with detailed segmentation on the basis of type, route of administration, indication, age group, end user, and key regions.
Type
Route of Administration
Indication
Age Group
End User
Region
Inactivated/Killed Vaccines
Live-attenuated Vaccines
Recombinant Vaccines
Intramuscular
Intranasal
Subcutaneous
Influenza
Measles, Mumps & Rubella
Coronavirus Disease (COVID-19)
Others
Pediatric
Adults
Physician Offices
Hospitals
Clinics
Pharmacies/Stores
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Respiratory Virus Vaccines Market Insights by Route of Administration
Based on route of administration, the market can be segmented into intramuscular, subcutaneous, and intranasal. Of these, the intramuscular segment is likely to remain dominant throughout the period of forecast.
Respiratory Virus Vaccines Market Insights by Indication
Based on indication, the global market can be classified into mumps & rubella, measles, influenza, coronavirus disease (COVID-19), and others. Of these, the influenza segment currently holds prominence. Rising cases of influenza around the world have made effective vaccination programs highly necessary for children. Over the coming years, the market will witness rising demand from the COVID-19 segment. In the absence of proper vaccination, governments around the world are leaving no stone unturned to discover a potential cure.
The Respiratory Virus Vaccines market report answers important questions which include:
What does the status of the Respiratory Virus Vaccines market look like after the forecast period?
Which region has the highest contribution to the global Respiratory Virus Vaccines market and why?
Which players remain at the top of the global Respiratory Virus Vaccines market?
What opportunities are available for the Respiratory Virus Vaccines market players to expand their production footprint?
Which segment has the maximum impact on the global Respiratory Virus Vaccines market?
Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape
Rising Burden of Respiratory Illnesses Fuelling Demand
According to the World Health Organization, nearly 290,000 to 650,000 people die every year around the world due to flu-related illnesses. Rising incidence of respiratory illnesses and subsequently increasing demand for vaccines to prevent respiratory infections are the chief drivers of the global market.
With leading pharmaceutical companies racing to be the first to develop and launch a vaccine for the novel coronavirus, the respiratory virus vaccines market is expected to surge exponentially through the course of the forecast period.
Why Opt For Fact.MR?
Various analysis methods to deliver precise market information.
Digital technologies to facilitate clients with updated market solutions.
Multi-disciplinary approach to provide accurate insights of different industries.
Data collection from extensive primary and secondary research.
Round-the-clock availability to serve clients across the world.
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact: US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583
Corporate Headquarter: Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates Email: sales@factmr.com Visit Our Website: https://www.factmr.com